Voyageur Pharmaceuticals Ltd V.VM

Alternate Symbol(s): VYYRF

Healthcare Drug Manufacturers - Specialty & Generic

Voyageur Pharmaceuticals Ltd. is a Canada-based company engaged in the development of barium and iodine Active Pharmaceutical Ingredients (API) and offers high-performance imaging contrast agents. The Company is focused on vertically integrating the barium and iodine contrast market, and aims at producing its own barium, iodine, and endo fullerenes. The Company’s products include SmoothX, SmoothHD, SmoothLD, VisionHD, VisionLD and V-Gas. SmoothX (2%w/v) is a contrast medium for use in computed tomography (CT) of the gastrointestinal tract. VisionHD is a high-density (98% w/w) barium powder suspension tailored for double-contrast radiographic examination of the gastrointestinal tract, esophagus, stomach and duodenum. It also owns a 100% interest in the Frances Creek barium sulfate (barite) project, which is a rare grade mineral suitable for the pharmaceutical marketplace that is intended to replace the current synthetic products with quality imaging products.

TSXV:VM - Post by User

Voyageur Pharmaceuticals Ltd > NASDAQ listing rules

<< Previous

Bullboard Posts

Next >>

Comment by postie1on Jan 05, 2025 9:27am

98 Views

Post# 36388352

RE:RE:RE:NASDAQ listing rules

From the way I read it not right now. But that does not change what I think of the companys' outlook near term. This agreement will be something to watch as i am curious to see what it brings to the pipeline ase VM seems to want to keep it natural and depending on how it is classed is what determines criteria for HC and FDA approval as well as cost to get it approved ?

<< Previous

Bullboard Posts

Next >>

Gold Flora's Gramlin holds court in California cannabis market